18F-PSMA-1007 PET/CT Superior to MRI for Staging Prostate Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, July 11, 2024 -- For men undergoing locoregional staging of prostate cancer, fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (18F-PSMA-1007 PET/CT) is superior to multiparametric magnetic resonance imaging (MRI), according to a study published online July 1 in JAMA Oncology to coincide with the annual meeting of the Canadian Urological Association, held from June 29 to July 1 in Victoria.

Nikhile Mookerji, M.D., from the University of Alberta in Edmonton, Canada, and colleagues determined the accuracy of 18F-PSMA-1007 PET/CT compared to multiparametric MRI in the primary locoregional staging of intermediate- and high-risk prostate cancers in the Next Generation Trial, a phase 2 study. Patients underwent all imaging studies and radical prostatectomies at two tertiary care hospitals; 134 of 150 eligible men with prostate cancer underwent radical prostatectomy.

The researchers found that compared with MRI, PSMA PET was significantly superior for the accurate identification of the final pathological tumor stage (45 versus 28 percent, respectively). In addition, PSMA PET was significantly superior for the correct identification of the dominant nodule (94 versus 83 percent), laterality (64 versus 44 percent), and extracapsular extension (75 versus 63 percent) compared with MRI but was not significantly superior for correct identification of seminal vesicle invasion.

"Future research should address the accuracy of combining PET/CT and MRI as well as cost effectiveness of PET/CT for the primary staging of men with prostate cancer," the authors write.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-12 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords